Advaxis completes patient enrollment in Phase II trial of ADXS-HPV
07:10 EDT 30 May 2012 | Pharmaceutical Business Review
Advaxis, a clinical-stage biotechnology company, has completed patient enrollment in Phase II trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
Original Article: Advaxis completes patient enrollment in Phase II trial of ADXS-HPV
More From BioPortfolio on "Advaxis completes patient enrollment in Phase II trial of ADXS-HPV"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
